BioSpace News Archive

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, highlighted four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel that were recently presented at the IDWeek conference in Boston, Massachusetts.

Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer.

Masimo (NASDAQ: MASI) will release third quarter 2023 financial results for the period ended September 30, 2023, after the market closes on Tuesday, November 7, 2023.

IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $125.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the U.S. financial markets.

Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217.

Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2023.

Owens & Minor, Inc. plans to release financial results for the third quarter of 2023 on Friday, November 3, 2023, before trading begins on the New York Stock Exchange.

egnite, Inc., a leading cardiovascular digital health company, announced today that novel research on aortic stenosis (AS) was presented by cardiologist Philippe Généreux, MD, Director of the Structural Heart Program of Morristown’s Gagnon Cardiovascular Institute, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.